From Yahoo Finance: 2025-06-02 10:54:00

Sanofi has agreed to acquire Blueprint Medicines for $9.1bn, adding rare immunology disease treatments like Ayvakit/Ayvakyt and an early-stage pipeline. This includes elenestinib and BLU-808, targeting systemic mastocytosis. The deal offers $129.00 per share in cash, with a potential total value of $9.5bn. Sanofi plans to finance using cash reserves and new debt.

Blueprint shareholders will receive a non-tradeable CVR for future milestone payments. The offer price represents a 27% premium on Blueprint’s closing price and a 34% premium over the 30-day VWAP. Sanofi CEO Paul Hudson sees this as a strategic move to strengthen their rare and immunology portfolios, aiming to become a leading immunology company.

Sanofi recently acquired Vigil Neuroscience for $470m, expanding their immunology offerings. The acquisition aligns with their goal of bringing differentiated medicines to patients and securing returns for shareholders. Sanofi plans to continue pursuing acquisitions in the future to bolster their therapeutic areas.



Read more at Yahoo Finance: Sanofi to expand immunology offerings with Blueprint Medicines